Zimbabwe has declined a substantial American healthcare agreement worth 367 million US dollars (272 million pounds) over five years due to Washington's demand for confidential data.
This rejection was revealed after a government memo dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesman later explained that the United States was seeking biological samples for research and commercial purposes but refused to share the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable task of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further talks to secure a deal acceptable to both sides so the nation's critical HIV treatment initiative can continue.
Broader Background
This development follows a similar case in Kenya, where a high court halted a related deal with the US after legal challenges were raised about the security of Kenyans' health data.
After resuming office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
USAID had administered aid for the US government, but Trump stated its spending was "wasteful" and his administration was seeking direct bilateral deals to enhance openness and accountability.
According to statements, Sixteen nations in Africa have to date signed similar health pacts, representing more than $18.3bn in committed funds.
Specifics of the Declined Agreement
The funds for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million men, women and children currently receiving HIV treatment through American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any corresponding assurance of access to any scientific breakthroughs – such as new medicines or tests – that might result from that shared data," he stated.
"Effectively, our nation would supply the raw materials for medical research without any assurance that the end products would be accessible to our citizens should a future health crisis emerge."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the global health body and its push of one-on-one deals were undermining systems previously set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to deal with potential pandemics.
"This system is designed to ensure that when a nation provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We encourage ongoing dialogue with our US partners on how future co-operation might be structured in a manner that respects the independence and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the government's concerns, but recommended that negotiations should continue considering much of the country's Aids initiatives relied on international support.
"In cases where technical issues arise, including those relating to information security or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," it added.
The situation emphasises the complex challenges between receiving vital foreign assistance and protecting a country's data in an ever more data-driven world.